A New Option for Treating High Blood Pressure is Available to United States Veterans
ST. CHARLES, Mo., May 16, 2025 /PRNewswire/ -- Hypertension, or high blood pressure, is known as the "silent killer" because many people do not know they have it and, over time, it can lead to serious health issues. In fact, hypertension increases the risk of heart disease and stroke, two of the leading causes of death in the United States. The 2020 Veterans Health Administration (VHA) guidelines on hypertension define uncontrolled hypertension as a reading above or equal to 130/90 mmHg.1 66% of veterans diagnosed with hypertension are considered uncontrolled by the VHA's guidelines.2
Hypertension treatment typically begins with a change in diet, like reducing salt intake, and physical exercise. For some, medication may also be prescribed. However, about one-third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these patients, medical device-based hypertension therapies, like the Paradise™ Ultrasound Renal Denervation (uRDN) system, may be an additional treatment option.
Army veteran Richard Van Name is one such patient who was looking for another way to treat his uncontrolled hypertension. An Army pilot for more than 30 years, Richard noticed his blood pressure was increasing during the later part of his service, and he was diagnosed with hypertension after retirement. Despite adjusting his lifestyle and taking progressively more medications, his blood pressure had not reached a normal level. That's when his physician recommended that he consider the Paradise uRDN treatment, a one-time, safe and minimally invasive procedure that is clinically proven to reduce blood pressure.3-6
"My blood pressure was starting to creep up in the last part of my career, but they were still within the limits for the military. When I was first diagnosed with hypertension, my blood pressure was 178 over 100. Diet and exercise did not bring it down any, and the medication brought it down to around the 150 to 160 region," said Richard. "My cardiologist was not satisfied that the maximum he had prescribed had not brought it down to where he thought was best. The doctor prescribed ultrasound renal denervation, and the procedure had definite results. My wife and I feel a lot better because it relieves us of the chances of heart attack or stroke."
The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy—lasting seven seconds each—through the main renal arteries to the surrounding nerves. The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall. This minimally invasive procedure is supported by many medical societies including the American Heart Association, the American College of Cardiology, the European Society of Cardiology and others.
Recor Medical—the manufacturer of the Paradise System—has partnered with Service-Disabled Veteran Owned Small Business (SDVOSB) Recon Supply to support the distribution of the Paradise System through the VHA and Department of Defense.
Recor has been focused on developing and testing uRDN for the treatment of hypertension since 2009, and completed three independently powered, sham-controlled, randomized clinical trials, all which demonstrate the efficacy and safety of the Paradise System, leading to FDA approval in late 2023. Recor has also initiated the US Global Paradise System (GPS) Post-Approval Study to collect real-world clinical evidence with long-term follow-up in 1,000 patients with uncontrolled hypertension in the United States.
The Paradise uRDN system is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. A physician will make a medical assessment to determine if a patient is a candidate for ultrasound renal denervation. The most common risks include pain, vascular access site complications and vasospasm. Full important risk information can be viewed here.
Defense DoVAaDo. VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension in the Primary Care Setting. 2020.
Yamada et al. J Hypertens. 2023 Apr 17;41(6):995–1002.
Azizi et al. JAMA. 2023;329(8):651-661.
Azizi et al. Lancet. 2018 Jun 9;391(10137):2335-2345.
Azizi et al. Lancet. 2021 Jun 26;397(10293):2476-2486.
Kirtane et al. JAMA Cardiol. 2023;8(5):464-473.
About Recon Supply Recon Supply is an SBA-certified Service-Disabled Veteran Owned Small Business (SDVOSB), demonstrating its commitment to serving the country both in and out of uniform. The company takes pride in its veteran-led team and its dedication to providing exceptional service to military and government clients. For more information on Recon Supply's offerings, visit www.Recon-Supply.com or contact Recon Supply at 314-317-0300.
About Recor Medical, Inc.Recor Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise uRDN system is an investigational device in Japan, is FDA approved in the United States, and bears the CE mark. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise uRDN system in patients with mild-to-moderate and resistant hypertension. In addition, Recor is conducting the Global Paradise System ("GPS") Registry in the European Union and the UK, and has initiated the US GPS post-approval study in the United States.
http://www.recormedical.com/
Media Contact Katy ClarkEmail - Katy@recon-supply.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/a-new-option-for-treating-high-blood-pressure-is-available-to-united-states-veterans-302457799.html
SOURCE Recon Supply
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 days ago
- Newsweek
VA Report Finds 'Severe' Staffing Shortages
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Department of Veterans Affairs is facing "severe" staffing shortages at its hospitals, with many struggling to fill jobs for doctors, nurses and psychologists, according to a new report from the agency's independent watchdog. The report from the VA's Office of Inspector General, released on Tuesday, said Veterans Health Administration (VHA) facilities reported 4,434 "severe occupational staffing shortages" in the 2025 fiscal year — a 50 percent increase from the 2024 fiscal year. The report is based on surveys taken at 139 VHA facilities from late March to early April. A Department of Veterans Affairs clinic in Daytona Beach, Florida, in July. A Department of Veterans Affairs clinic in Daytona Beach, Florida, in July. Phelan M. Ebenhack/AP Photo Why It Matters The VHA is the largest integrated healthcare system in the United States, providing care to millions of veterans each year. The surveys that the report was based on were taken after it was reported that the VA planned to cut 80,000 jobs — out of roughly 484,000 — through the so-called Department of Government Efficiency. The VA later reduced that figure to nearly 30,000 jobs cuts by the end of the fiscal year. Veteran Affairs Secretary Doug Collins said that staff cuts would not affect care, but the report's findings raise concerns about a lack of essential healthcare staff in VA facilities. What To Know The report found that nearly all of the facilities (94 percent) surveyed reported a shortage of medical officer occupations including doctors, while 79 percent reported shortages of nurses. But the report noted that severe shortages for medical officers and nurses have been identified every year since 2014. The report also said that at least 20 percent of facilities identified severe staffing shortages for 43 occupations overall, the highest number since 2018. Psychology was the "most frequently reported clinical occupational staffing shortage," with 57 percent of facilities reporting a lack of staff. The top reported shortage for non-clinical positions was for police officers, with 58 percent of facilities reporting it. Pete Kasperowicz, the VA's press secretary, said in a statement that the report was "not a reliable indicator of staffing shortages." But Representative Mark Takano, the ranking Democrat on the House Committee on Veterans' Affairs, said the report confirms fears that the VA is facing staffing shortages leading to "decreased access and choice for veterans." What People Are Saying Kasperowicz, the VA's press secretary, said in a statement: "The report simply lists occupations facilities feel are difficult for which to recruit and retain, so the results are completely subjective, not standardized and unreliable." Takano said that the report "confirms our fears: VA and veterans are worse off under Doug Collins's leadership. Instead of making VA an employer of choice, Secretary Collins continues to vilify the VA workforce and strip them of their rights. Now, VA is facing critical staffing shortages across the country, leading to decreased access and choice for veterans. Veterans deserve and have earned better." What Happens Next Further staffing shortages are expected as the department continues to reduce staff through hiring freezes, deferred resignations, retirements and attrition by the end of the fiscal year. Meanwhile, ProPublica reported last week that veterans hospitals are struggling to replace the doctors and nurses who have left the healthcare system this year. Records show that almost 40 percent of doctors offered jobs from January through March turned them down.
Business Wire
2 days ago
- Business Wire
Grove Biopharma to Participate in Materials Biology Symposium at ACS Fall 2025 Scientific Meeting
CHICAGO--(BUSINESS WIRE)--Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, announced today it will present an update at the annual American Chemical Society (ACS) Fall meeting being held August 17-21, 2025, in Washington D.C. This symposium spotlights how advances in modern polymer chemistry and materials science are informing our understanding of biology Share The symposium, taking place on Monday, August 18 and titled Materials Biology: Precision Macromolecules for Probing and Perturbing Cellular Processes, will include presentations about peptide, protein and glycomimetic materials and the critical role they play in understanding and impacting human disease. These insights have the potential to unlock new therapeutic strategies in the development of next-generation medicines. 'This symposium spotlights how advances in modern polymer chemistry and materials science are informing our understanding of biology,' said Nathan Gianneschi, Ph.D., Scientific Founder of Grove Biopharma and Professor at Northwestern University. 'By designing synthetic polymers that can precisely interact with cells and proteins at the same scale as natural biomolecules, we are opening new pathways to study and influence complex cellular processes. This emerging field, what we call 'materials biology', is focused on the role of synthetic precision macromolecules and nanomaterials in understanding the natural world.' 'At Grove, we are pioneering Bionic Biologics—a new class of therapeutics that integrates biologic and synthetic design, accelerated by computation, to develop molecules capable of selectively inhibiting or degrading even the most challenging intracellular targets,' said Paul Bertin, Ph.D., Co-Founder, President and Chief Technology Officer at Grove Biopharma. 'By integrating protein and peptide engineering, precision polymer chemistry and medicinal chemistry, we can create fully synthetic, cell penetrant, protein-scale molecules to address complex protein-scale problems. We see the potential for Bionic Biologics in oncology and neurodegenerative diseases, offering a novel alternative to existing approaches.' About Grove Biopharma Grove Biopharma is a private biotechnology company pioneering its proprietary Bionic Biologics™ platform to develop novel therapies targeting intracellular protein-protein interactions. Bionic Biologics represent a novel therapeutic modality that integrates principles of biologic and synthetic design. This innovative platform enables the targeting of well-validated yet previously intractable disease drivers, unlocking new possibilities for therapeutic intervention. A spinout from Northwestern University, Grove brings together a multidisciplinary team of chemists, biologists, materials scientists and entrepreneurs. The company is based in Chicago, embedded within the city's emerging life sciences ecosystem. For more information, please visit
Medscape
2 days ago
- Medscape
Weight Loss Before Military Training May Cut Injury Risk
TOPLINE: Army recruits who lost excess weight to enter military training experienced fewer musculoskeletal injuries (MSKIs), particularly in the lower extremities, during basic combat training than those who did not lose weight to join the service. METHODOLOGY: The nation's obesity epidemic means that fewer individuals meet the US Army's weight and body-fat standards for entering basic combat training. Only 29% of 17- to 24-year-olds in the country would have qualified to join the military in 2018, with overweight and obesity among the leading disqualifying factors. Researchers analyzed data from 3168 Army trainees (mean age, 20.96 years; 62.34% men; mean maximum-ever BMI, 26.71) to examine the association between weight loss before enlistment and rates of MSKI during basic combat training. Trainees completed a baseline questionnaire that asked whether the person lost weight to enter the Army and included follow-up questions about the amount of weight lost, duration of weight loss, methods used, and prior physical activity. MSKIs were classified as any injury to the musculoskeletal system and further categorized by body region (lower extremities, upper extremities, spine/back, and other areas, including the torso and head/neck). Researchers identified MSKIs from medical records collected throughout basic combat training and for up to 6 weeks afterward to capture injuries that occurred during training but were documented only after its completion. TAKEAWAY: Overall, 829 trainees (26.16%) reported losing weight to enter the Army, and they tended to have higher mean maximum-ever BMI, body-fat percentage, and lean mass compared with those who did not lose weight to join the service. The mean weight loss was 9.06 kg at a rate of 1.27 kg/wk among the 723 trainees with complete data. The most commonly reported weight-loss methods were exercising more (83.72%), changing diet (61.04%), skipping meals (39.32%), and sweating using a sauna or rubber suit (25.57%). Trainees who lost weight to join the service had a lower risk of any MSKI (hazard ratio [HR], 0.86) and lower extremity MSKIs (HR, 0.84) during training than those who did not lose weight to enter the Army. No difference was found between the two groups in the risk of upper extremity, spine/back, or other MSKIs. Among trainees who lost weight to join the Army, the amount of time it took to lose weight was not associated with the risk for any MSKI or region-specific MSKIs. IN PRACTICE: "The findings highlight that losing excess weight before entering military training may reduce MSKI risk for incoming recruits, enforcing the benefits of healthy weight loss programs," the authors wrote. SOURCE: The study, led by Vy T. Nguyen, MS, DSc, Military Performance Division, US Army Research Institute of Environmental Medicine, Natick, Massachusetts, was published online in Obesity. LIMITATIONS: The study did not assess whether the association between weight loss and the rate of MSKIs persisted over long-term military service. How the two most frequently reported weight loss methods — increased exercise and dietary changes — may have influenced the observed association remains unclear. Medical records may not have captured all MSKIs if trainees did not seek medical care due to concerns about graduating on time or being placed on limited duty. DISCLOSURES: The study was supported by the US Army Medical Research and Development Command's Military Operational Medicine Program. Two authors received support from the funder. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
